Low-Molecular-Weight Heparin Is More Effective Than Aspirin in Preventing Early Neurologic Deterioration and Improving Six-Month Outcome
Authors:
- 1 July 2014
- journal article
- research article
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 23 (6) , 1537-1544
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Aspirin Resistance in Chinese Stroke Patients Increased the Rate of Recurrent Stroke and other Vascular EventsInternational Journal of Stroke, 2012
- Low-Molecular-Weight Heparin Versus Aspirin for Acute Ischemic Stroke With Large Artery Occlusive DiseaseStroke, 2012
- Aspirin and Extended-Release Dipyridamole versus Clopidogrel for Recurrent StrokeNew England Journal of Medicine, 2008
- Stroke-free Survival and Its Determinants in Patients with Symptomatic Vertebrobasilar Stenosis: A Multicenter StudyNeurosurgery, 2003
- Thrombolytic stroke therapyNeurology, 1999
- Antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid arteryNeurology, 1999
- Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)The Lancet, 1998
- Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke: A Randomized Controlled TrialJAMA, 1998
- CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic strokeThe Lancet, 1997
- Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic StrokeNew England Journal of Medicine, 1995